Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer: Secret weapons in anti-cancer war?

Monica Marra, Aldo Giudice, Claudio Arra, Giovanni Vitale, Sara Castiglioni, Guglielmo Nasti, Angela Lombardi, Alessandro Ottaiano, Gaetano Facchini, Rosario V. Iaffaioli, Alberto Abbruzzese, Michele Caraglia

Research output: Contribution to journalArticlepeer-review

Abstract

The therapeutic options for liver metastases of colorectal cancer mainly include surgical resection and palliative chemotherapy. More recently, the increased availability of new and more active cytotoxic drugs has increased the appeal of a combined treatment strategy, in which chemotherapy is administered before surgery. However, the efficacy of neoadjuvant chemotherapy of CRC liver metastases is limited by: (1) the persistence of micro metastatic foci that cannot be seen by conventional imaging techniques, placed either in other sites throughout the liver and/or in the site of the previous macroscopic metastasis that has undergone to clinical complete response; (2) the occurrence of escape mechanisms. The molecular basis regulating these processes are described and the first clinical attempts to overcome these mechanisms through the use of target-based agents are also reported. Finally, biological rationales to optimize the activity of these agents in neoadjuvant setting are discussed.

Original languageEnglish
Pages (from-to)1709-1718
Number of pages10
JournalCancer Biology and Therapy
Volume8
Issue number18
Publication statusPublished - Sep 15 2009

Keywords

  • Angiogenesis
  • Colorectal cancer
  • Liver metastases
  • Neoadjuvant therapy
  • Target-based agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer: Secret weapons in anti-cancer war?'. Together they form a unique fingerprint.

Cite this